# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA779633 | F | In vivo effective dose against Cholesterol Biosynthesis in rats by oral administration | Rattus norvegicus | 1 | organism-based format | Scientific Literature | ||
2. | ALA781991 | F | In vivo intravenous effective dose against cholesterol biosynthesis in rats | Rattus norvegicus | 12 | organism-based format | Scientific Literature | ||
3. | ALA784697 | F | Compound was tested for inhibition of cholesterol biosynthesis in rats by intravenous (iv) dosing. | Rattus norvegicus | 7 | organism-based format | Scientific Literature | ||
4. | ALA880206 | F | Compound was tested for inhibition of cholesterol biosynthesis in rats by oral dosing (po). | Rattus norvegicus | 14 | organism-based format | Scientific Literature | ||
5. | ALA808970 | B | Inhibitory activity against rat liver microsomal squalene synthase was determined using [3H]FPP as radioligand | 25 | assay format | Scientific Literature | |||
6. | ALA941163 | B | Inhibition of Staphylococcus aureus dehydrosqualene synthase expressed in Escherichia coli BL21 (DE3) cells by continuous spectrophotometric assay | Staphylococcus aureus | 38 | cell-based format | Scientific Literature | ||
7. | ALA941164 | F | Inhibition of staphyloxanthin biosynthesis in Staphylococcus aureus Pig1 isolate after 72 hrs | Staphylococcus aureus | 38 | organism-based format | Scientific Literature | ||
8. | ALA941165 | B | Inhibition of human recombinant squalene synthase expressed in Escherichia coli BL21 (DE3) cells assessed as formation of 1,10-dioic acid metabolite by liquid scintillation | Homo sapiens | 38 | cell-based format | Scientific Literature | ||
9. | ALA3829382 | F | Attenuation of methicillin-resistant Staphylococcus aureus Mu 50 virulence in BALB/c mouse systemic infection model assessed as decrease in bacterial survival in liver at 200 mg/kg, ip administered every 12 hrs for 108 hrs followed by bacterial challenge after first 12 hrs of compound dosing measured 5 days post infection | Staphylococcus aureus | 2 | organism-based format | Scientific Literature | ||
10. | ALA3830152 | F | Attenuation of methicillin-resistant Staphylococcus aureus USA400 MW2 virulence in BALB/c mouse systemic infection model assessed as decrease in bacterial burden in liver at 200 mg/kg, ip administered every 12 hrs for 108 hrs followed by bacterial challenge after first 12 hrs of compound dosing measured 5 days post infection | Staphylococcus aureus | 2 | organism-based format | Scientific Literature | ||
11. | ALA3830153 | F | Attenuation of methicillin-resistant Staphylococcus aureus USA400 MW2 virulence in BALB/c mouse systemic infection model assessed as decrease in bacterial burden in liver at 50 mg/kg, ip administered every 12 hrs for 108 hrs followed by bacterial challenge after first 12 hrs of compound dosing measured 5 days post infection | Staphylococcus aureus | 2 | organism-based format | Scientific Literature | ||
12. | ALA3830156 | F | Attenuation of methicillin-resistant Staphylococcus aureus Mu 50 virulence in BALB/c mouse systemic infection model assessed as decrease in bacterial survival in liver at 50 mg/kg, ip administered every 12 hrs for 108 hrs followed by bacterial challenge after first 12 hrs of compound dosing measured 5 days post infection | Staphylococcus aureus | 2 | organism-based format | Scientific Literature | ||
13. | ALA3830157 | F | Attenuation of methicillin-resistant Staphylococcus aureus Mu 50 virulence in BALB/c mouse systemic infection model assessed as decrease in bacterial survival in kidney at 200 mg/kg, ip administered every 12 hrs for 108 hrs followed by bacterial challenge after first 12 hrs of compound dosing measured 5 days post infection | Staphylococcus aureus | 2 | organism-based format | Scientific Literature | ||
14. | ALA3830158 | F | Attenuation of methicillin-resistant Staphylococcus aureus Mu 50 virulence in BALB/c mouse systemic infection model assessed as decrease in bacterial survival in kidney at 50 mg/kg, ip administered every 12 hrs for 108 hrs followed by bacterial challenge after first 12 hrs of compound dosing measured 5 days post infection | Staphylococcus aureus | 2 | organism-based format | Scientific Literature | ||
15. | ALA3830163 | B | Inhibition of Staphylococcus aureus ATCC 27659 full length His-tagged dehydrosqualene synthase expressed in Escherichia coli BL21 (DE3) cells assessed as reduction in staphyloxanthin pigment formation after 72 hrs by spectrophotometric analysis | Staphylococcus aureus | 1 | cell-based format | Scientific Literature | ||
16. | ALA4008294 | B | Inhibition of Staphylococcus aureus ATCC 27659 histidine-tagged full length CrtM expressed in Escherichia coli BL21(DE3) cells assessed as decrease in staphyloxanthin formation after 30 mins by continous spectrophotometric method | Staphylococcus aureus | 1 | cell-based format | Scientific Literature | ||
17. | ALA4027795 | B | Inhibition of CrtM in Staphylococcus aureus assessed as reduction in staphyloxanthin levels after 72 hrs by spectrophotometric method | Staphylococcus aureus | 1 | single protein format | Scientific Literature |